Wcn24-409 Efficacy of Direct Oral Anticoagulants in Patients With Nephrotic Syndrome: A Multi-Institutional Analysis

Patients with nephrotic syndrome possess an increased risk of venous and arterial thromboembolism due to complex changes in the levels of circulating clotting factors and natural anticoagulants, in addition to increased platelet activation. This increased risk of vascular events has been shown to correlate with the severity of hypoalbuminemia. Warfarin, lowmolecular-weight heparin, and aspirin have been studied and used to prevent and treat vascular events in these patients, but little is known about the efficacy and safety of the newer direct oral anticoagulants (DOACs) in this setting.